Optineurin Negatively Regulates Osteoclast Differentiation by Modulating NF-κB and Interferon Signaling

Implications for Paget's Disease

Rami Obaid, Sachin E. Wani, Asim Azfer, Toby Hurd, Ruth Jones, Philip Cohen, Stuart H. Ralston, Omar Al Bagha

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Paget's disease of bone (PDB) is a common disease characterized by osteoclast activation that leads to various skeletal complications. Susceptibility to PDB is mediated by a common variant at the optineurin (OPTN) locus, which is associated with reduced levels of mRNA. However, it is unclear how this leads to the development of PDB. Here, we show that OPTN acts as a negative regulator of osteoclast differentiation in vitro and that mice with a loss-of-function mutation in Optn have increased osteoclast activity and bone turnover. Osteoclasts derived from Optn mutant mice have an increase in NF-κB activation and a reduction in interferon beta expression in response to RANKL when compared to wild-type mice. These studies identify OPTN as a regulator of bone resorption and are consistent with a model whereby genetically determined reductions in OPTN expression predispose to PDB by enhancing osteoclast differentiation. Using mouse models, Obaid et al. identify a role of optineurin in bone metabolism as a negative regulator of osteoclast differentiation. Loss of optineurin function leads to increased bone turnover in mice, suggesting a mechanism by which genetic variants in optineurin predispose to Paget's disease of bone.

Original languageEnglish
Pages (from-to)1096-1102
Number of pages7
JournalCell Reports
Volume13
Issue number6
DOIs
Publication statusPublished - 10 Nov 2015
Externally publishedYes

Fingerprint

Osteitis Deformans
Osteoclasts
Interferons
Bone
Bone Remodeling
Interferon-beta
Bone Resorption
Chemical activation
Metabolism
Bone and Bones
Messenger RNA
Mutation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Optineurin Negatively Regulates Osteoclast Differentiation by Modulating NF-κB and Interferon Signaling : Implications for Paget's Disease. / Obaid, Rami; Wani, Sachin E.; Azfer, Asim; Hurd, Toby; Jones, Ruth; Cohen, Philip; Ralston, Stuart H.; Al Bagha, Omar.

In: Cell Reports, Vol. 13, No. 6, 10.11.2015, p. 1096-1102.

Research output: Contribution to journalArticle

Obaid, Rami ; Wani, Sachin E. ; Azfer, Asim ; Hurd, Toby ; Jones, Ruth ; Cohen, Philip ; Ralston, Stuart H. ; Al Bagha, Omar. / Optineurin Negatively Regulates Osteoclast Differentiation by Modulating NF-κB and Interferon Signaling : Implications for Paget's Disease. In: Cell Reports. 2015 ; Vol. 13, No. 6. pp. 1096-1102.
@article{f8ad4496e339485d9ab3d8ff607baca4,
title = "Optineurin Negatively Regulates Osteoclast Differentiation by Modulating NF-κB and Interferon Signaling: Implications for Paget's Disease",
abstract = "Paget's disease of bone (PDB) is a common disease characterized by osteoclast activation that leads to various skeletal complications. Susceptibility to PDB is mediated by a common variant at the optineurin (OPTN) locus, which is associated with reduced levels of mRNA. However, it is unclear how this leads to the development of PDB. Here, we show that OPTN acts as a negative regulator of osteoclast differentiation in vitro and that mice with a loss-of-function mutation in Optn have increased osteoclast activity and bone turnover. Osteoclasts derived from Optn mutant mice have an increase in NF-κB activation and a reduction in interferon beta expression in response to RANKL when compared to wild-type mice. These studies identify OPTN as a regulator of bone resorption and are consistent with a model whereby genetically determined reductions in OPTN expression predispose to PDB by enhancing osteoclast differentiation. Using mouse models, Obaid et al. identify a role of optineurin in bone metabolism as a negative regulator of osteoclast differentiation. Loss of optineurin function leads to increased bone turnover in mice, suggesting a mechanism by which genetic variants in optineurin predispose to Paget's disease of bone.",
author = "Rami Obaid and Wani, {Sachin E.} and Asim Azfer and Toby Hurd and Ruth Jones and Philip Cohen and Ralston, {Stuart H.} and {Al Bagha}, Omar",
year = "2015",
month = "11",
day = "10",
doi = "10.1016/j.celrep.2015.09.071",
language = "English",
volume = "13",
pages = "1096--1102",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "6",

}

TY - JOUR

T1 - Optineurin Negatively Regulates Osteoclast Differentiation by Modulating NF-κB and Interferon Signaling

T2 - Implications for Paget's Disease

AU - Obaid, Rami

AU - Wani, Sachin E.

AU - Azfer, Asim

AU - Hurd, Toby

AU - Jones, Ruth

AU - Cohen, Philip

AU - Ralston, Stuart H.

AU - Al Bagha, Omar

PY - 2015/11/10

Y1 - 2015/11/10

N2 - Paget's disease of bone (PDB) is a common disease characterized by osteoclast activation that leads to various skeletal complications. Susceptibility to PDB is mediated by a common variant at the optineurin (OPTN) locus, which is associated with reduced levels of mRNA. However, it is unclear how this leads to the development of PDB. Here, we show that OPTN acts as a negative regulator of osteoclast differentiation in vitro and that mice with a loss-of-function mutation in Optn have increased osteoclast activity and bone turnover. Osteoclasts derived from Optn mutant mice have an increase in NF-κB activation and a reduction in interferon beta expression in response to RANKL when compared to wild-type mice. These studies identify OPTN as a regulator of bone resorption and are consistent with a model whereby genetically determined reductions in OPTN expression predispose to PDB by enhancing osteoclast differentiation. Using mouse models, Obaid et al. identify a role of optineurin in bone metabolism as a negative regulator of osteoclast differentiation. Loss of optineurin function leads to increased bone turnover in mice, suggesting a mechanism by which genetic variants in optineurin predispose to Paget's disease of bone.

AB - Paget's disease of bone (PDB) is a common disease characterized by osteoclast activation that leads to various skeletal complications. Susceptibility to PDB is mediated by a common variant at the optineurin (OPTN) locus, which is associated with reduced levels of mRNA. However, it is unclear how this leads to the development of PDB. Here, we show that OPTN acts as a negative regulator of osteoclast differentiation in vitro and that mice with a loss-of-function mutation in Optn have increased osteoclast activity and bone turnover. Osteoclasts derived from Optn mutant mice have an increase in NF-κB activation and a reduction in interferon beta expression in response to RANKL when compared to wild-type mice. These studies identify OPTN as a regulator of bone resorption and are consistent with a model whereby genetically determined reductions in OPTN expression predispose to PDB by enhancing osteoclast differentiation. Using mouse models, Obaid et al. identify a role of optineurin in bone metabolism as a negative regulator of osteoclast differentiation. Loss of optineurin function leads to increased bone turnover in mice, suggesting a mechanism by which genetic variants in optineurin predispose to Paget's disease of bone.

UR - http://www.scopus.com/inward/record.url?scp=84946836881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946836881&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2015.09.071

DO - 10.1016/j.celrep.2015.09.071

M3 - Article

VL - 13

SP - 1096

EP - 1102

JO - Cell Reports

JF - Cell Reports

SN - 2211-1247

IS - 6

ER -